Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:
- Pracinostat, an oral HDAC inhibitor;
- ME-401, an oral PI3K delta inhibitor;
- Voruciclib, an oral CDK inhibitor; and
- ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.
Pracinostat HDAC Inhibitor
Acute Myeloid Leukemia
Unfit for intensive chemotherapy
High & very high risk
PI3K Delta Inhibitor
ME-401 PI3K Delta Inhibitor
• Rituxan® (rituximab)
Selective CDK Inhibitor
Voruciclib CDK Inhibitor
ME-344 Mitochondrial Inhibitor
Treatment-naïve, early stage
† Phase 2 study intended to support an accelerated approval marketing application with the FDA
‡ Study arm to be initiated under clinical collaboration with Beigene, Ltd.
§ Investigator-initiated study